Forward P/S Multiple: Bone Biologics Corp (BBLG)
The projected P/S metric on this GURU.Markets platform chart, where the parameter value reaches , correlates with the dominance of Bone Biologics (BBLG) in the spinal regeneration niche due to patent protection. Production capacities for matrix output operate strictly according to industry standards. This strengthens its status as a biotech innovator, building physician trust by accelerating the healing of complex fractures.
Summary analytical data breakdowns for Bone Biologics Inc (BBLG)
- market price and analyst price targets:
- company stock exchange capitalization indicators:
- issuer book value statistics:
- debt and liquidity data:
Total Debt to Capital Bone Biologics|BBLG - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Bone Biologics|BBLG - Company Aggregate Debts|Debt to Book Capitalization Ratio Bone Biologics Inc|BBLG - Company Long-Term Debt|Company Current Liabilities Bone Biologics|Quick Ratio bonebiologics.com
- financial results and valuation multiples details:
BBLG - Company Net Income|Expected Profit Bone Biologics|BBLG - Market Cap to Net Income Ratio|Projected Price to Earnings Bone Biologics Corporation|BBLG - PEG Multiple|EV/EBITDA Multiple Bone Biologics Inc|BBLG - Operating income before deduction of amortization|Earnings per share for the last twelve months Bone Biologics|BBLG - Earnings per one share for the last 12 months|Year-over-year earnings per share growth for the last twelve months bonebiologics.com|BBLG - Net earnings per share growth this year|Earnings growth forecast for next year Bone Biologics
- sales and revenue indicators:
Fundamental company analysis:BBLG (Bone Biologics Corp)
The forward P/S reflects the market value of Bone Biologics (BBLG) relative to its expected annual revenue, allowing for an assessment of investor optimism regarding future cash flows. Analyzing the issuer's forward P/S reveals how a high speculative premium offsets the lack of current regulatory approvals, leaving the business extremely vulnerable to any technological failures or changes in the cost of debt.
Who Bone Biologics competes with
Price-to-Projected Revenue Ratio Boston Scientific Corporation BSX|EW - Forward Price-to-Revenue Multiple|ResMed Corp - Forward P/S Multiple|Market Cap to Future Revenue Ratio Insulet Inc.|ZBH: Forward P/S Multiple|Market Cap to Projected Revenue COO|ALGN (Align Technology) - Forward P/S Multiple|Globus Medical Inc (GMED) - Market Cap to Expected Sales Ratio|Forward P/S Multiple TMDX|Forward Price-to-Revenue Multiple Alphatec Corp ATEC|Forward P/S Multiple AORT (Artivion, Inc.)|Forward P/S Multiple enovis.com ENOV|IART - Price-to-Projected Revenue Ratio|ESTA: Price-to-Projected Revenue Ratio|BBNX (Beta Bionics Corp) - Forward Price-to-Revenue Multiple|IRADIMED Inc. - Forward Price to Sales|EMBC (Embecta Corp.) - Forward P/S Multiple|Market Cap to Future Revenue Ratio tandemdiabetes.com TNDM|Price-to-Projected Revenue Ratio Axogen (AXGN)|SI-BONE Inc (SIBN) - Projected Price to Revenue|Orthofix International - Forward Price-to-Revenue Multiple|Forward P/S Multiple Bioventus Global BVS|OrthoPediatrics Inc. - Forward P/S Multiple|Market Cap to Expected Sales Ratio treace.com TMCI|Strata Critical Medical (SRTA) - Price-to-Projected Revenue Ratio|Future Price to Revenue CARL (Carlsmed, Inc.)|Price-to-Projected Revenue Ratio RxSight Corp|Forward Price-to-Revenue Multiple ClearPoint (CLPT)|Forward P/S Multiple STXS|STIM - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio Sight Sciences SGHT|OBIO: Market Cap to Projected Revenue|ANIK: Forward Price-to-Revenue Multiple|InspireMD Inc. - Price to Expected Revenue Ratio|ZJYL: Forward P/S Multiple|VANI (Vivani Medical) - Price-to-Projected Revenue Ratio|Price-to-Projected Revenue Ratio Xtant Medical Holdings, Inc.|Market Cap to Future Revenue Ratio NeuroOne NMTC|Price-to-Projected Revenue Ratio Modular Medical (MODD)|Myomo Inc - Market Cap to Projected Revenue|Forward P/S Multiple COCH (Envoy Medical, Inc.)|vivoslife.com (VVOS) - Market Cap to Future Revenue Ratio|NVNO: Forward Price-to-Revenue Multiple|Forward Price to Sales SINT (Sintx Technologies)|TNON: Forward P/S Multiple|LFWD (Lifeward Ltd.) - Price-to-Projected Revenue Ratio|AMIX (Autonomix Medical Inc.) - Forward P/S Multiple|invobioscience.com (IVF) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Axonics (AXNX)|BIOL - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio Dynatronics DYNT|Paragon 28 Inc. - Price-to-Projected Revenue Ratio|INVO - Price-to-Projected Revenue Ratio
